APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

NCT04214860 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloid Malignancy

Interventions

DRUG: APR-246
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Aprea Therapeutics